{"prompt": "['6.5 Adverse Event (AE), Pregnancy Exposure, and Incident Reporting', 'As this is a low-interventional study that does not involve an investigational product the', 'occurrence of adverse events is anticipated to be none to extremely low. Adverse event', 'reporting will be managed in line with the study-specific pharmacovigilance plan (sPVP)', 'that will be completed and filed internally at GSK. If a participant mentions during the', 'interview any adverse event (AE) or product complaint, whether it is considered serious', 'or not, experienced whilst taking a product produced by GSK, this must be reported to', 'the pharmacovigilance department at GSK. The interviewer will complete an adverse', 'event monitoring report form (Error! Reference source not found.) at the end of the', 'interview that will capture information regarding the reportable event and the GSK', 'product involved and the role of the person reporting the event. As part of this process', \"the interviewer will seek the participant's permission to include their contract details and\", 'the contact details of their physician on the form; however, should a participant not', 'choose to include their contact details on the AE form, they will be informed that the AE', 'still has to be reported, but will be done so anonymously. Any completed forms will be', 'sent to the designated contact at GSK within 24 hours of awareness of the adverse', 'event or adverse drug reaction.', '7', 'EXTERNAL INVOLVEMENT', '7.1', 'Third Party Supplier', 'Supplier', 'Address', 'Staff contact details', 'Adelphi Values', 'Adelphi Mill', 'Senior Lead: PPD', '(Company conducting', 'Grimshaw Lane', 'PPD', 'the study)', 'Bollington', 'Project Lead:', 'PPD', 'Macclesfield', 'PPD', 'SK10 5JB', 'Researcher: PPD', 'PPD', 'Project administrator:', 'PPD', 'PPD', 'MedQuest Global', 'MedQuest Global', 'PPD', '(Recruiter)', '30460 Cartagena Place,', 'Castaic, CA 91384', 'Zeste Germany', 'Zeste Research', '(Recruiter)', 'Stockheimerstrasse', '297647 Willmars,', 'Germany', 'Transperfect', 'Transperfect', 'GK7818Av7_0', 'Page 33 of 131', 'Effective: 20 Jan 2017']['(Transcription', 'Three Park Avenue', 'PPD', 'agency)', '39th Floor', 'New York, NY 10016', 'LumiGlobal', 'LumiGlobal', '(App vendor)', 'Lumi USA', '510 First Avenue North', 'Suite 222', 'Minneapolis', 'USA', 'MN 55403', '7.2 External Expert/Health Care Professionals (Consultants & Research PIs)', 'Not applicable', '8 REFERENCES', '1.', 'US Food and Drug Administration. Guidance for industry: patient-reported', 'outcome measures: use in medical product development to support labeling', 'claims. 2009.', '2.', 'European Medicines Agency Comittee for Medicinal Products for Human Use.', 'Reflection paper on the regulatory guidance for the use of health-related quality', 'of life (HRQL) measures in the evaluation of medicinal products. 2005.', '3.', 'Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size?', 'Operationalising data saturation for theory-based interview studies. Psychology', 'and Health. 2010;25(10):1229-1245.', '4.', 'Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment', 'with data saturation and variability. Field methods. 2006;18(1):59-82.', '5.', 'Fokkens W, Lund V, Bachert C, et al. EAACI position paper on rhinosinusitis and', 'nasal polyps executive summary. Allergy. 2005;60(5):583-601.', '6.', 'Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance', 'for clinical trials. Journal of Allergy and Clinical Immunology. 2006;118(5):S17-', 'S61.', '7.', 'Piccirillo JF, Merritt MG, Richards ML. Psychometric and clinimetric validity of the', '20-item Sino-Nasal Outcome Test (SNOT-20). Otolaryngology-Head and Neck', 'Surgery. 2002;126(1):41-47.', '8.', 'Hopkins C, Gillett S, Slack R, Lund V, Browne J. Psychometric validity of the 22-', 'item Sinonasal Outcome Test. Clinical otolaryngology. 2009;34(5):447-454.', 'GK7818Av7_0', 'Page 34 of 131', 'Effective: 20 Jan 2017']\n\n###\n\n", "completion": "END"}